A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (anti-CD20) Antibody, Etoposide and Cyclophosphamide followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgkin's Lymphoma.

Trial Profile

A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (anti-CD20) Antibody, Etoposide and Cyclophosphamide followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgkin's Lymphoma.

Not stated
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2010

At a glance

  • Drugs Iodine-131 tositumomab (Primary) ; Cyclophosphamide; Etoposide
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Aug 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top